Novo Nordisk discontinues inflammation R&D

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) is discontinuing all inflammatory disease R&D. Novo ended development of its lead compound in the space, NN8226, which is a recombinant human mAb neutralizing IL-20 in Phase II trials to treat rheumatoid arthritis (RA). In February, Novo discontinued development of NN8828, a recombinant human mAb against IL-21 that was in Phase II trials to treat Crohn's disease (CD).

Novo said the decision affects about 400 employees, of which about half will be offered other positions. ...